Overview
Zeus is pleased to announce that it has acted as Sole Broker in the £12.5m fundraise for Avacta Group plc (AVCT).
Net proceeds will provide working capital to extend the Company’s cash runway and to progress the pre|CISION® platform technology: to continue to develop AVA6103, to continue the ongoing trial with faridoxorubicin (AVA6000), and to progress its Next-Generation dual-payload asset (AVA6207).
Company information
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform.
Contact
If you would like further information, please get in touch with our team.
This web page constitutes a financial promotion for the purposes of section 21 of the Financial Services and Markets Act 2000 and has been approved by Zeus Capital Limited, which is authorised and regulated by the Financial Conduct Authority.